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Abstract
The pathogenesis of Graves’ orbitopathy (GO) is not completely understood. Coexistent hyperfunction of the thyroid gland is 
frequent; however, GO may also coexist with hypo- or euthyrodism. The course of GO is largely independent of thyroid func-
tion, although elevated serum TSH is known to negatively interfere with GO course. GO is severe in 10% of the cases; sight 
threatening complications may also develop. A successful therapy of GO requires the assesment of both the severity and activity 
of orbital inflammation. Based on relevant studies and our own experiences, the possible management choices are reviewed 
here. For this purpose, we compare the clinical value of imaging techniques for detecting the activity of the disease. During the 
last 15 years, we used 99mTc-DTPA retrobulbar SPECT routinely in more than 1400 patients to facilitate the right therapeutic 
decision. This diagnostic utility simplified management decisions compared to previously applied alternative techniques. We 
recommended the routine use of 99mTc-DTPA retrobulbar SPECT for the evaluation and follow-up of GO.
KEY words: GO, 99mTc-DTPA, hyperthyroidism
Nucl Med Rev 2018; 21, 1: 47–51
Introduction
Graves’ orbitopathy (GO) is an autoimmune disease charac-
terized by exophthalmos, caused by the enlargement of external 
eye muscles, and an increase in the volume of connective tissue 
in the orbital space. As part of the autoimmune process, the 
orbital space is infiltrated by immunocompetent cells, especially 
macrophages, plasma cells, lymphocytes, and mast cells. Orbital 
fibroblasts are thought to play a crucial role in the pathogenesis by 
their ability to produce strongly hydrophilic glycosaminoglycans, 
resulting in fluid retention and edematous swelling of the orbital 
tissue. It is important to note that the immunological activity and 
clinical severity of GO are following separate courses, and activity 
is the primary determinant of the response to immunosuppressive 
treatment [1, 2]. In an early stage of disease, marked immune ac-
tivity may be accompanied by only moderate clinical signs, while 
later severe clinical presentation may equally be present with or 
without immune activity, as shown by Rundle as early as in 1960 
[3]. Determining the activity of GO at each clinical assessment 
is fundamental in the planning of the appropriate management. 
Immunomodulatory therapies can only be effective while there 
is active inflammation. On the other hand, surgery involving the 
external eye muscles for the correction of diplopia should only be 
undertaken when GO is inactive, and there is no further chance 
of change in muscle function due to fluctuating immune activ-
ity. The major and easiest approach to assess the activity is the 
estimation of the clinical activity score (CAS), first described by 
Mourits in 1997 [4]. However, CAS is also influenced by anterior 
segment changes, and easily over- or underestimates disease 
activity (Nagy et al.) [5]. Up till now, no reliable serum factors have 
been identified which could estimate immune activity in GO. For 
long, a highly reproducible and quantifiable method for disease 
activity estimation has been missing [6]. In the present review, 
we summarize the multidisciplinary approach to the activity and 
severity of GO, proposing a diagnostic strategy.
Current diagnostic methods
Approach of Clinical Endocrinology 
The hormonal investigation and follow-up of patients with GO 
are in the traditional scope of endocrinology. The thyroid hormonal 
status and measurements of antibody concentrations belong here. 
Usually higher TSH receptor antibody levels accompany active 
orbital inflammation; however, low antibody levels do not exclude 
active GO. During the treatment of Graves’ hyperthyroidism, over-
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treatment resulting in high serum TSH should be avoided, as it may 
negatively interfere with the course of GO [7].
Ophthalmology
The patients suffering from GO usually turn to, or are referred 
to an ophthalmologist. The measurement and scoring of visual 
symptoms and signs remains essential for patient management. 
While the NOSPECT classification [8] describes disease severity, for 
disease activity, the clinical activity score (CAS) is the gold stand-
ard. However, there is little or no correlations between the severity 
and activity of GO. Eye movement is assessed by the Hess chart. 
Proptosis is measured by Hertel ophthalmometer. The main limiting 
factor of any ophthalmological scoring system is that it is based 
on findings on the anterior orbital segment; as the immune activity 
is hidden in the orbit, only indirect information can be obtained 
about the immune process.
Non-nuclear imaging
In GO, it is essential to check the anatomy of the intra orbital 
space to assess the cause and severity of exophthalmus. MRI 
is suitable for showing the fat and orbital connective tissue, and can 
describe the condition of the lacrimal glands and the ophthalmic 
nerves [9, 10]. Prolongation of the T2 relaxation time in the eye 
muscles is a reliable MRI marker of disease activity in the muscles. 
However, other components of the orbital space, including fatty 
connective tissue, are often not correctly graded for inflammation 
by MRI. “A” mode ultrasonography of the eye muscles may be use-
ful for detecting disease activity in the muscles and monitoring the 
changes; however, limited eye movement limits the angles of the 
ultrasound probe to be used for muscle diameter measurement.
Methods of nuclear medicine
Since nuclear medicine techniques can provide the functional 
information mentioned in the introduction that are essential for as-
sessing disease activity, their use in clinical practice has attracted 
increasing attention. For a long time, in the planar gamma camera 
era, both the lack of GO-specific radiopharmaceuticals, and the 
poor spatial resolution prevented a nuclear medicine approach. 
First in 1999, 111In-octreotide [11–13] and labelled polyclonal human 
immunoglobulin [14] were tested to estimate the activity of GO. 
Although these methods have been accepted for the evaluation 
of GO activity, they are considered research approaches, as high 
cost remains a serious drawback. Recently, more cost-effective 
radioisotope methods have been introduced, with higher spatial 
resolution of the orbital space by SPECT. This enabled us to numeri-
cally grade the immune activity of GO. These methods meet the 
requirements listed above, and are becoming part of patient care 
in endocrinology, ophthalmology, and radiation therapy.
Imaging method
The details of DTPA orbital SPECT were described earlier [15]. 
Briefly, a double- or four-headed SPECT system is pre-calibrated 
for eye SPECT quantitation with a small amount of 99mTc. We ad-
minister 7 MBq/kg 99mTc-DTPA, recording the time of measurement 
for later uptake activity (UA) calculation. Twenty minutes after the 
intravenous injection, a four-headed SPECT (MEDISO, Budapest, 
Hungary) is routinely used for the acquisition of 128 projections in 
step-and-shoot mode over 360 degrees. For data analysis, the 
DIAG and INTERVIEW software packages (MEDISO, Hungary) are 
used. After reconstruction and attenuation correction, we select 
and summarize 12 consecutive coronal, sagittal and transversal 
slices for visual interpretation (Figure 1).
For UA calculation, a summed transversal slice with 24.6 mm 
thickness centered on the eye-balls is used. The retrobulbar re-
gions of interest (ROIs) are delineated, from which the activities in 
unit volume, expressed as proportions of the injected dose, are 
calculated. The upper normal UA value, based on disease-free 
orbits, was found to be 12⋅106 ID/mL [15, 16] (Figure 2). Occasion-
ally orbitopathy may be one-sided (Figure 3).
In 2002 we compared DTPA SPECT data with MRI, and found 
good correlation regarding disease activity. It appears likely that 
DTPA SPECT may be comparable to octreotide and other poly-
peptide SPECT results. The clinical usefulness of DTPA SPECT 
has been proven by several clinical studies from our institution 
[17]. Although factors of the initiation and perpetuation of the au-
toimmune process in GO remain unclear [18], quantitative data of 
orbital inflammation in GO are essential for appropriate treatment 
choices. In disease activity measurement and prognosis estimation 
[19], the UA has been shown a useful parameter in GO by inde-
pendent authors [20]. Based on our early experience with DTPA 
orbital SPECT, we included it in the routine clinical evaluation of GO; 
we have performed more than 1400 orbital DTPA SPECTs during 
the last 15 years.
DTPA uptake values, other diagnostic methods, and 
treatment outcome
We compared DTPA SPECT with MRI images, and found a good 
correlation. It appears likely that DTPA images are comparable 
to octreotide and other polypeptide SPECT results; our clinical 
studies proved the usefulness of DTPA. While understanding 
the immuno-pathogenesis of GO is evolving, the clinicians need 
well-established quantitative indices of inflammation in GO; so, 
we tested the method for staging and follow-up of patients [21, 
Figure 1. Sequence of 2 mm slices in transaxial, sagittal and coronal 
planes after data acquisition, filtered back projection, and attenuation 
correction. Altogether 12 slices are summarized in which the volume 
of orbital space is included. Left, from up to down: sum of 34–45 
transaxial slices, sum of 13–24 right, 40–52 left sagittal, and 17–28 
coronal slices are shown. For UA calculation we draw ROIs on 
selected transaxial slices, producing VOIs of the orbital regions (See 
Fig. 2). The cold area of eye globe helps the correct orientation
49www.nmr.viamedica.pl
László Galuska et al., 99mTc-DTPA retrobulbar SPECT
Review
22]. In the last 10 years we use a protocol of GO patient manage-
ment, which includes information obtainable by different imaging 
techniques. Diagnostic and therapeutic measures in GO patient 
Figure 2. Typical group of 12 summarized slices from 3, previously 
mentioned (Fig 1) planes, which are printed as part of the final report 
on a patient suffering from GO. The high DTPA uptake is visible as 
red-colored area (arrow) in the region of the medial eye muscle on 
both sides. The UA values were 13 (right) and 15⋅106 ID/mL (left orbital 
region), showing both sided active GO
Figure 3. Asymmetric, mainly right-sided GO. The UA on the right and 
left side were 15.1, and 9.2, respectively
Figure 4. The suggested workup for GO. The flow chart includes 
imaging techniques at the major points of decision (in frames). The 
preferable method is SPECT if thyroid disease is present, while MR is 
the first choice if there are no thyroid dysfunction or thyroid antibodies 
(Immediate MR is required for the assessment of the optic nerve if 
visual acuity deteriorates any time during the course of GO)
Suspected GO
Endocrinology and Ophthalmology  No GO            
GO present 
Thyroid tests positive  Thyroid tests negative
GO proven   Stop 
Active disease Inactive disease
Immunosupression 
Active disease Follow up
(corticisteroid ± irradiation)
Stop 
Orbital imaging for diff. Diagnosis
MRI (exclude tumors)
Other than GO
Orbital imaging for 
disease activity 
DTPA SPECT or
MR ± T2 relax. time
Ophthalmo-surgical 
interventions
decompression
 lid correction
 diplopia
Orbital imaging for 
disease activity 
DTPA SPECT or
MR ± T2 relax. time Inactive disease 
with residual signs
Inactive disease 
with improving signs
Second line
 treatements
management, including the DTPA orbital SPECT, are summarized 
in the flow chart (Figure 4).
Using our flow chart in clinical routine patient care, the first 
specialists who most frequently meet patients with suspected GO 
are the ophthalmologists.
After careful physical ophthalmological examination and the 
calculation of the clinical activity score (CAS), the next important 
diagnostic question is the biological activity of GO. MRI may exclude 
intra orbital tumor, and T2 relaxation time measurements in the 
affected muscles can help the activity estimation of GO. Some-
times the UA values are in the normal range, but the signs of 
inflammation are visible outside of the orbital space, in the frontal 
and facial sinus areas (Figure 5). In cases with symptoms of newly 
diagnosed or relapsed GO, and a CAS suggestive of an active GO 
(CAS ≥ 4), DTPA eye SPECT is indicated. For patients with initially 
normal or low DTPA uptake, steroid treatment or external irradia-
tion had poor prognosis. In case of these patient other therapeutic 
measures, as decompressive surgery, fat removal (lipectomy), 
double vision correction, etc., should be considered (Figure 6). 
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Conclusions
99mTc-DTPA is a well-known traditional radiopharmaceutical 
[23, 24]. More than 15 years ago we introduced DTPA orbital 
SPECT in the clinical management of endocrine patients suffering 
in GO. Our method of orbital UA quantification has proved to be 
suitable for the selection of EOP patients, providing good or poor 
prognosis of steroid or external irradiation therapy, as well as oph-
thalmologic interventions. Recently, a new software allows faster 
data analysis (Figure 7).
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